Teaching the body

to fight cancer again.

NOVEL ONCOLYTIC IMMUNOTHERAPY

CARs

CHIMERIC ANTIGEN RECEPTORs
Showing promising early results in cancer oncology, CAR-T cell therapy genetically modifies a patient’s T-cells, reactivating and retargeting the immune system to kill tumor cells. As with most early-stage treatments, CAR-T therapy is complex and not without potential side effects—short- and long-term.

PARs

®

:

THE CARs
ALTERNATIVE

PROSTHETIC ANTIGEN RECEPTORs

Tychon® introduces PARs®, which harnesses the power of protein dimerization to produce chemically self-assembling nanorings (CSANs). These nanorings form a stable, flexible construct to combine a patient’s T lymphocytes (T-cells) and a host of cancer-seeking antigens, creating a wide variety of adoptive cell therapies (PARs®) with selective anti-tumor capabilities.

PARs ADVANTAGES

NANORINGS.
NOT GENETIC CHANGES.

Nanoring-based PARs reactivate & retarget the immune system without
the cost or long-term risks of genetic modification.

COMPLETELY REVERSIBLE THERAPY.

No need for suicide genes or viral
vectors. FDA-approved antibiotic Trimethoprim is all it takes to
dissolve the CSANs (nanorings) and
switch PARs off.

MORE EFFECTIVE FOR PATIENTS & PROVIDERS.

A cheaper, faster, more flexible and controllable way to deliver
personalized oncolytic
immunotherapy.

OUR GOAL:

To create a viable
alternative to surgery,
radiation & chemotherapy.

TYCHON

®

WILL BE ENTERING CLINICAL TRIALS

EMAIL

info@tychonbio.com

PHONE

+1 612 200 1039

OFFICE

227 Colfax Ave N, Ste 148 Minneapolis, MN 55405